One Capital Management LLC increased its stake in shares of Allergan PLC. (NYSE:AGN) by 3.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 12,553 shares of the company’s stock after buying an additional 423 shares during the quarter. One Capital Management LLC’s holdings in Allergan PLC. were worth $3,052,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Jacobi Capital Management LLC grew its holdings in shares of Allergan PLC. by 4.9% during the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock worth $112,000 after buying an additional 22 shares during the last quarter. JNBA Financial Advisors grew its holdings in shares of Allergan PLC. by 2.5% during the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock worth $116,000 after buying an additional 12 shares during the last quarter. Webster Bank N. A. grew its holdings in shares of Allergan PLC. by 31.0% during the first quarter. Webster Bank N. A. now owns 520 shares of the company’s stock worth $124,000 after buying an additional 123 shares during the last quarter. Pacific Center for Financial Services grew its holdings in shares of Allergan PLC. by 805.1% during the first quarter. Pacific Center for Financial Services now owns 534 shares of the company’s stock worth $128,000 after buying an additional 475 shares during the last quarter. Finally, Ropes Wealth Advisors LLC grew its holdings in shares of Allergan PLC. by 31.0% during the first quarter. Ropes Wealth Advisors LLC now owns 575 shares of the company’s stock worth $137,000 after buying an additional 136 shares during the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Allergan PLC. (NYSE AGN) opened at 231.21 on Wednesday. Allergan PLC. has a 52-week low of $184.50 and a 52-week high of $256.80. The firm has a market capitalization of $77.29 billion, a P/E ratio of 7.04 and a beta of 1.18. The stock’s 50 day moving average is $235.09 and its 200-day moving average is $237.04.
Allergan PLC. (NYSE:AGN) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.95 by $0.07. The business had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The business’s revenue was up 8.8% on a year-over-year basis. During the same period last year, the firm posted $3.35 earnings per share. On average, equities analysts forecast that Allergan PLC. will post $16.25 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be issued a $0.70 dividend. This represents a $2.80 annualized dividend and a dividend yield of 1.21%. The ex-dividend date of this dividend is Wednesday, August 16th. Allergan PLC.’s dividend payout ratio (DPR) is presently 9.95%.
TRADEMARK VIOLATION NOTICE: “One Capital Management LLC Grows Position in Allergan PLC. (AGN)” was originally published by Stock Observer and is owned by of Stock Observer. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.thestockobserver.com/2017/09/13/one-capital-management-llc-grows-position-in-allergan-plc-agn.html.
A number of equities analysts recently issued reports on the company. Mizuho reissued a “buy” rating and set a $267.00 price target on shares of Allergan PLC. in a report on Wednesday, August 2nd. Royal Bank Of Canada set a $285.00 price target on Allergan PLC. and gave the stock a “buy” rating in a report on Thursday, August 3rd. Wells Fargo & Company raised their price target on Allergan PLC. to $278.00 and gave the stock an “outperform” rating in a report on Thursday, August 3rd. Deutsche Bank AG reissued a “buy” rating and set a $273.00 price target (up previously from $265.00) on shares of Allergan PLC. in a report on Monday, July 17th. Finally, BidaskClub raised Allergan PLC. from a “hold” rating to a “buy” rating in a report on Saturday, June 24th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $274.69.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.